The role of influenza vaccination in the prevention of pulmonary and cardiovascular diseases

Abstract

Influenza is an acute respiratory disease that causes annual epidemics and periodic pandemics with high mortality. It is characterized by the development of severe complications, the main of which are pulmonary and cardiovascular ones. The only effective method of preventing influenza, and therefore the influenza-associated complications, is vaccination, which is carried out annually on the basis of World Health Organization influenza vaccines composition recommendations. This article provides the review of the research data confirming the effective role of influenza vaccination in the prevention of pulmonary and cardiovascular pathologies (bibliography: 12 refs).

Keywords

cardiovascular diseases / complications / influenza / pulmonary diseases / vaccination

References

[1] Kiselev OI, Tsybalova LM, Pokrovsky VI, ed. Influenza: epidemiology, clinical presentation, prevention. Influenza – the view of the virologist and the attending physician. Moscow: LLC Medical Information Agency Publisher; 2012. 496 p. (In Russ.)

[2] Грипп: эпидемиология, клиника, профилактика. Грипп — взгляд вирусолога и лечащего врача / под ред. О.И. Киселева, Л.М. Цыбаловой, В.И. Покровского. М.: Медицинское информационное агентство, 2012. 496 с.

[3] Danilenko DM, Sominina AA, Komissarov AB, et al. The effectiveness of influenza vaccination in reducing the frequency of hospitalizations, assessed at different stages of the epidemic cycle. Epidemiology and Vaccinoprophylaxis. 2019;18(5):63–69. (In Russ.)

[4] Даниленко Д.М., Соминина А.А., Комиссаров А.Б., и др. Эффективность вакцинации от гриппа в снижении частоты госпитализаций, оцененная на разных стадиях эпидемического цикла // Эпидемиология и вакцинопрофилактика. 2019. Т. 18, № 5. C. 63–69.

[5] Characteristics of the influenza epidemic of the 2019–2020 season. In Russian federation. Report of the WHO National Influenza Centers in the Russian Federation. St. Petersburg, 2020. (In Russ.)

[6] Характеристика эпидемии гриппа сезона 2019–2020 гг. в Российской Федерации. Отчет национальных центров по гриппу ВОЗ в РФ. Санкт-Петербург, 2020 г.

[7] Daoud A, Laktineh A. Macrander C. Mushtaq A. Soubani AO. Pulmonary complications of influenza infection: a targeted narrative review. Postgraduate Medicine. 2019;131(5):299–308.

[8] Daoud A., Laktineh A., Macrander C., Mushtaq A., Soubani A.O. Pulmonary complications of influenza infection: a targeted narrative review // Postgraduate Medicine. 2019. Vol. 131, No. 5. P. 299–308.

[9] Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518–527.

[10] Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature // Ann. Intern. Med. 1995. Vol. 123, No. 7. P. 518–527.

[11] Nichol KL., Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130(5): 397–403. DOI: 10.7326/0003-4819-130-5-199903020-00003

[12] Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease // Ann. Intern. Med. 1999. Vol. 130, No. 5. P. 397–403. DOI: 10.7326/0003-4819-130-5-199903020-00003

[13] Puig-Barberà J, Márquez-Calderón S, Masoliver-Fores A, et al. Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain. J Epidemiol Community Health. 1997;51(5):526–530. DOI: 10.1136/jech.51.5.526

[14] Puig-Barberà J., Márquez-Calderón S., Masoliver-Fores A., et al. Reduction in hospital admissions for pneumonia in non-institutionalised elderly people as a result of influenza vaccination: a case-control study in Spain // J. Epidemiol. Community Health. 1997. Vol. 51, No. 5. P. 526–530. DOI: 10.1136/jech.51.5.526

[15] Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1999;17 Suppl 1:91–93. DOI: 10.1016/s0264-410x(99)00114-0

[16] Nichol K.L. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease // Vaccine. 1999. No. 17 Suppl 1. P. 91–93. DOI: 10.1016/s0264-410x(99)00114-0

[17] MacIntyre CR., Mahimbo A, Moa AM., Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. Heart. 2016;102(24):1953–1956.

[18] MacIntyre C.R., Mahimbo A., Moa A.M., Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction // Heart. 2016. Vol. 102, No. 24. P. 1953–1956.

[19] Caldeira D, Ferreira JJ, Costa J. Influenza vaccination and prevention of cardiovascular disease mortality. Lancet. 2018;391(10119):426–427.

[20] Caldeira D., Ferreira J.J., Costa J. Influenza vaccination and prevention of cardiovascular disease mortality // Lancet. 2018. Vol. 391, No. 10119. P. 426–427.

[21] Sen A, Bakken IJ, Govatsmark RES, et al. Influenza vaccination and risk for cardiovascular events: a nationwide self-controlled case series study. BMC Cardiovascular Disorders. 2021;21:31.

[22] Sen A., Bakken I.J., Govatsmark R.E.S. et al. Influenza vaccination and risk for cardiovascular events: a nationwide self-controlled case series study // BMC Cardiovascular Disorders. 2021. No. 21. P. 31.

[23] Zangiabadian M, Nejadghaderi SA, Mirsaeidi M, et al. Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis. Scientific Reports. 2020;10(1):20656.

[24] Zangiabadian M., Nejadghaderi S.A., Mirsaeidi M., et al. Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis // Scientific Reports. 2020. Vol. 10, No. 1. P. 20656.

RIGHTS & PERMISSIONS

Vasin A.V.